Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer

Benzer Materyaller

• A phase I, pharmacokinetic and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors
  Yazar:: Gray, Jhanelle E., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
  Yazar:: Creelan, Ben C., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer
  Yazar:: Bepler, Gerold, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma
  Yazar:: Creelan, Ben C., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
  Yazar:: Chiappori, Alberto A., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)